verezdoВестник репродуктивного здоровьяBulletin of Reproductive Health2075-65692310-421XEndocrinology Research Centre (Moscow)10.14341/brh12767verezdo-12767Research ArticleНАУЧНЫЕ ОБЗОРЫREVIEWSМолочная железа: фокус на метаболическое здоровьеMammary Gland: Focus on metabolic healthВеснинаА. Ф.VesninaA. F.

Веснина Анна Федоровна, к.м.н.

117036, Москва, ул. Дм. Ульянова, д. 11

Anna F. Vesnina, PhD

 11 Dm. Ulyanova street, 117036 Moscow

annvesnina@yandex.ruhttps://orcid.org/0000-0001-8425-0020АндрееваЕ. Н.AndreevaE. N.

Андреева Елена Николаевна, д.м.н., профессор

 Москва

Elena N. Andreeva, MD, PhD, Professor

Moscow

endogin@mail.ruhttps://orcid.org/0000-0002-3126-3132УжеговаЖ. А.UzhegovaZh. A.

Ужегова Жанна Александровна 

 Москва

Zhanna A. Uzhegova, MD, PhD

Moscow

ГНЦ РФ ФГБУ «НМИЦ эндокринологии им. академика И.И. Дедова» Минздрава РоссииРоссияEndocrinology Research Centre named after аcademician I.I. DedovRussian FederationГНЦ РФ ФГБУ «НМИЦ эндокринологии им. академика И.И. Дедова» Минздрава России; ФГБОУ ВО Российский университет медицины Минздрава РоссииRussian FederationEndocrinology Research Centre named after аcademician I.I. Dedov; Russian University of MedicineRussian Federation202515072025423747Copyright © Веснина А.Ф., Андреева Е.Н., Ужегова Ж.А., 20252025Веснина А.Ф., Андреева Е.Н., Ужегова Ж.А.Vesnina A.F., Andreeva E.N., Uzhegova Z.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.vrz-endojournals.ru/jour/article/view/12767

В данном обзоре рассматриваются актуальные представления об этапности развития патологических диспластических процессов в молочных железах, данные обзоров и метаанализов по изучению причин их развития, факторов прогрессирования, риск их дальнейшего влияния на формирование рака молочной железы. Рассматривается использование лекарственного препарата селективного модулятора эстрогеновых рецепторов как этиопатогенетической коррекции существующей у пациентки доброкачественной дисплазии молочных желёз как основной патологической ее причины, так и фактора риска дальнейшей пролиферативной и митотической активности — длительно существующей гиперэстрогении, оценены результаты клинических исследований в реальной клинической практике.

This review considers current ideas about the stages of development of pathological dysplastic processes in the mammary glands, data from reviews and meta-analyzes to study the causes of their development, factors of progression, the risk of their further influence on the formation of breast cancer. The use of a selective estrogen receptor modulator drug is considered as an etiopathogenetic correction of the patient’s existing disease, as its main pathological cause, and a risk factor for further proliferative and mitotic activity — long-term hyperestrogenism, the results of clinical studies in real clinical practice were evaluated.

доброкачественная дисплазия молочных железфиброзно-кистозная мастопатиярак молочной железыгиперэстрогенияожирениемастодиниявыделения из молочных железbenign breast diseaselong-term risk of breast cancerfibrocystic breast disease breast cancerhyperestrogeniaobesitymastodyniabreast dischargeReferencesSouthey MC, Winship I, Nguyen-Dumont T. PALB2: research reaching to clinical outcomes for women with breast cancer. Hered Cancer Clin Pract. 2016;14(1):9. doi: https://doi.org/10.1186/s13053-016-0049-2Southey MC, Winship I, Nguyen-Dumont T. PALB2: research reaching to clinical outcomes for women with breast cancer. Hered Cancer Clin Pract. 2016;14(1):9. doi: https://doi.org/10.1186/s13053-016-0049-2Kolak A, Kamińska M, Sygit K, et al. Primary and secondary prevention of breast cancer. Ann Agric Environ Med. 2017;24(4):549-553. doi: https://doi.org/10.26444/aaem/75943Kolak A, Kamińska M, Sygit K, et al. Primary and secondary prevention of breast cancer. Ann Agric Environ Med. 2017;24(4):549-553. doi: https://doi.org/10.26444/aaem/75943Bodewes FTH, van Asselt AA, Dorrius MD, Greuter MJW, de Bock GH. Mammographic breast density and the risk of breast cancer: A systematic review and meta-analysis. Breast. 2022;66:62-68. doi: https://doi.org/10.1016/j.breast.2022.09.007Bodewes FTH, van Asselt AA, Dorrius MD, Greuter MJW, de Bock GH. Mammographic breast density and the risk of breast cancer: A systematic review and meta-analysis. Breast. 2022;66:62-68. doi: https://doi.org/10.1016/j.breast.2022.09.007Ghosh K, Vierkant RA, Frank RD, Winham S, Visscher DW, et al. Association between mammographic breast density and histologic features of benign breast disease. Breast Cancer Res. 2017;19(1):134Ghosh K, Vierkant RA, Frank RD, Winham S, Visscher DW, et al. Association between mammographic breast density and histologic features of benign breast disease. Breast Cancer Res. 2017;19(1):134Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ. 2007;335(7630):1134. doi: https://doi.org/10.1136/bmj.39367.495995.AEReeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ. 2007;335(7630):1134. doi: https://doi.org/10.1136/bmj.39367.495995.AERaglan O, Kalliala I, Markozannes G, Cividini S, Gunter MJ, et al. Risk factors for endometrial cancer: An umbrella review of the literature. Int J Cancer. 2019;145:1719–30Raglan O, Kalliala I, Markozannes G, Cividini S, Gunter MJ, et al. Risk factors for endometrial cancer: An umbrella review of the literature. Int J Cancer. 2019;145:1719–30Zhao H, Yang H, Li Z, Ge Z, Zhou M, Li L, He J. Urine levels of estrogen and its metabolites in premenopausal middle-aged women with different degrees of obesity and their correlation with glucose and lipid metabolism. Heliyon. 2023;9(11):e22362Zhao H, Yang H, Li Z, Ge Z, Zhou M, Li L, He J. Urine levels of estrogen and its metabolites in premenopausal middle-aged women with different degrees of obesity and their correlation with glucose and lipid metabolism. Heliyon. 2023;9(11):e22362Байлюк Е.Н. Клинико-морфологические особенности пролиферативных процессов в молочной железе у больных миомой матки // Ж. акуш. и жен. болезн. — 2010. — №1 — С. 98-105Baylyuk E. N. Clinicomorphologic features of proliferative processes in mammary gland of patients with uterine myoma/ E. N. Baylyuk // Journal of Obstetrics and Women’s diseases. Issue 1. — 2010. — T. LIX. — pp. 98-105.Zhao C, Shang A, Wu H, Li Q, Peng L, Yue C. Causal relationship between genetically predicted uterine leiomyoma and cancer risk: a two-sample Mendelian randomization. Front Endocrinol (Lausanne). 2024 Aug 29;15:1429165. doi: https://doi.org/10.3389/fendo.2024.1429165Zhao C, Shang A, Wu H, Li Q, Peng L, Yue C. Causal relationship between genetically predicted uterine leiomyoma and cancer risk: a two-sample Mendelian randomization. Front Endocrinol (Lausanne). 2024 Aug 29;15:1429165. doi: https://doi.org/10.3389/fendo.2024.1429165Овсянникова Т.В. Возможности терапии дисгормональной патологии молочных желез у женщин с гинекологическими заболеваниями. // Акушерство, гинекология и репродукция. — 2010. — Т.4. — №2. — С. 28-32 [ Ovsyannikova T.V., Abilities of therapy for dyshormonal mammary gland pathology in females with gynecological diseases / Obstetrics, gynecology and reproduction. — 2010. — Vol.4. — No. 2. — pp. 28-32]11.Collins LC, Aroner SA, Connolly JL, Colditz GA, Schnitt SJ, Tamimi RM. Breast cancer risk by extent and type of atypical hyperplasia: An update from the Nurses’ Health Studies. Cancer. 2016;122(4):515-20. doi: https://doi.org/10.1002/cncr.29775Ovsyannikova T.V., Abilities of therapy for dyshormonal mammary gland pathology in females with gynecological diseases / Obstetrics, gynecology and reproduction. — 2010. — Vol.4. — No. 2. — pp. 28-32Visscher DW, Frost MH, Hartmann LC, Frank RD, Vierkant RA, et al. Clinicopathologic features of breast cancers that develop in women with previous benign breast disease. Cancer. 2016;122(3):378-85. doi: https://doi.org/10.1002/cncr.29766Collins LC, Aroner SA, Connolly JL, Colditz GA, Schnitt SJ, Tamimi RM. Breast cancer risk by extent and type of atypical hyperplasia: An update from the Nurses’ Health Studies. Cancer. 2016;122(4):515-20. doi: https://doi.org/10.1002/cncr.29775Ruan X, et al. The ratio of the estradiol metabolites 2-hydroxyestrone (2-OHE1) and 16α-hydroxyestrone (16-OHE1) may predict breast cancer risk in postmenopausal but not in premenopausal women: two case-control studies. Arch Gynecol Obstet. 2015;291(5)Visscher DW, Frost MH, Hartmann LC, Frank RD, Vierkant RA, et al. Clinicopathologic features of breast cancers that develop in women with previous benign breast disease. Cancer. 2016;122(3):378-85. doi: https://doi.org/10.1002/cncr.29766Zhao H, Yang H, Li Z, Ge Z, Zhou M, Li L, He J. Urine levels of estrogen and its metabolites in premenopausal middle-aged women with different degrees of obesity and their correlation with glucose and lipid metabolism. Heliyon. 2023;9(11):e22362Ruan X, et al. The ratio of the estradiol metabolites 2-hydroxyestrone (2-OHE1) and 16α-hydroxyestrone (16-OHE1) may predict breast cancer risk in postmenopausal but not in premenopausal women: two case-control studies. Arch Gynecol Obstet. 2015;291(5)Harvie M, et al. Randomised controlled trial of intermittent vs continuous energy restriction during chemotherapy for early breast cancer. Br J Cancer. 2022;126(8):1157-1167Zhao H, Yang H, Li Z, Ge Z, Zhou M, Li L, He J. Urine levels of estrogen and its metabolites in premenopausal middle-aged women with different degrees of obesity and their correlation with glucose and lipid metabolism. Heliyon. 2023;9(11):e22362Краснопольская К.В., Балан В.Е., Ершова И.Ю., и соавт. Масталгия при бесплодии: поиск дополнительных возможностей терапии // Гинекология. — 2021. — №4. doi: https://doi.org/10.26442/20795696.2021.4.201084Harvie M, et al. Randomised controlled trial of intermittent vs continuous energy restriction during chemotherapy for early breast cancer. Br J Cancer. 2022;126(8):1157-1167Сметник В.П., Гависова А.А., Билак Н.П., Друх В.М. Эффективность индолкарбинола при циклической мастодинии. // Проблемы репродукции. — 2013. — №5. — С. 4953Krasnopolskaya KV, Balan VE, Ershova IYu, Skorik EO, Malygin SE, Orazov MR, Toktar LR, Lagutina EV. Mastalgia in infertility: search for additional possibilities of therapy. Gynecology. 2021;23(4):354–363. doi: https://doi.org/10.26442/20795696.2021.4.201084Amarakoon D, Lee W-J, Tamia G, Lee S-H. Indole-3-Carbinol: Occurrence, Health-Beneficial Properties, and Cellular/Molecular Mechanisms. Annu Rev Food Sci Technol. 2023;14(1):347-366. doi: https://doi.org/10.1146/annurev-food-060721-025531Smetnik V.P., Gavisova A.A., Bilak N.P., Drukh V.M. Indolecarbinol efficacy for mastalgia treatment. Russian Journal of Human Reproduction. 2013;(5):49-53.Вандеева Е.Н., Протасова А.Э., Раскин Г.А., Ярмолинская М.И. Морфологические особенности доброкачественной дисплазии молочной железы у женщин с эндометриоз-ассоциированным бесплодием // РМЖ. Медицинское обозрение. — 2018. — № 10. — С. 22–25Amarakoon D, Lee W-J, Tamia G, Lee S-H. Indole-3-Carbinol: Occurrence, Health-Beneficial Properties, and Cellular/Molecular Mechanisms. Annu Rev Food Sci Technol. 2023;14(1):347-366. doi: https://doi.org/10.1146/annurev-food-060721-025531Тагиева, Тарана Теймур кызы. Фиброзно-кистозная болезнь молочных желез в практике гинеколога: диагностика, прогнозирование, тактика ведения: автореф. дис. ... доктора медицинских наук: 14.00.01 / Тагиева Тарана Теймур кызы; [Место защиты: Науч. центр акушерства, гинекологии и перинатологии РАМН]. — Москва, 2009. — 46 с.Vandeeva E.N., Protasova A.E., Raskin G.A., Yarmolinskaya M.I. Morphological features of benign mammary dysplasia in women with endometriosis-associated infertility // RMJ. Medical Review. 2018. № 10. P. 22–25.Farland L V., Tamimi RM, Heather Eliassen A, et al. A prospective study of endometriosis and risk of benign breast disease. Breast Cancer Res Treat. 2016;159(3):545-552. doi: https://doi.org/10.1007/s10549-016-3957-yTagieva, Tarana Teymur kyzy. Fibrocystic breast disease in gynecologist’s practice: diagnosis, prognosis, management tactics: abstract of the dissertation... Doctor of Medical Sciences: 14.00.01 / Tagieva Tarana Teymur kyzy; [Place of protection: Scientific Center of Obstetrics, Gynecology and Perinatology of the Russian Academy of Medical Sciences. — Moscow, 2009. — 46 p.Байлюк, Е. Н.Клинико-морфологические особенности пролиферативных процессов в молочной железе у больных миомой матки : диссертация ... кандидата медицинских наук : 14.00.01 / Байлюк Евгений Николаевич; [Место защиты: ГУ «Научно-исследовательский институт акушерства и гинекологии РАМН»]. - Санкт-Петербург, 2008. - 117 с. : 31 ил.Farland L V., Tamimi RM, Heather Eliassen A, et al. A prospective study of endometriosis and risk of benign breast disease. Breast Cancer Res Treat. 2016;159(3):545-552. doi: https://doi.org/10.1007/s10549-016-3957-yDyrstad SW, Yan Y, Fowler AM, Colditz GA. Breast cancer risk associated with benign breast disease: systematic review and meta-analysis. Breast Cancer Res Treat. 2015;149(3):569-575. doi: https://doi.org/10.1007/s10549-014-3254-6Baylyuk, E. N. Clinical and morphological features of proliferative processes in the mammary gland in patients with uterine fibroids : dissertation... Candidate of Medical Sciences : 14.00.01 / Bailyuk Evgeny Nikolaevich; [Place of defense: State Institution «Scientific Research Institute of Obstetrics and Gynecology of the Russian Academy of Medical Sciences». - Saint Petersburg, 2008. - 117 p. : 31 ill.Travis RC, Key TJ. Oestrogen exposure and breast cancer risk. Breast Cancer Res. 2003;5(5):239. doi: https://doi.org/10.1186/bcr628Dyrstad SW, Yan Y, Fowler AM, Colditz GA. Breast cancer risk associated with benign breast disease: systematic review and meta-analysis. Breast Cancer Res Treat. 2015;149(3):569-575. doi: https://doi.org/10.1007/s10549-014-3254-6Кит О.И., Франциянц Е.М., Бандовкина В.А., Шатова Ю.С., Комарова Е.Ф., Верескунова М.И., Кучкина Л.П. Содержание метаболитов эстрона в периферических жидкостях и тканях у женщин, больных раком молочной железы, разного возраста и репродуктивного статуса // Фундаментальные исследования. — 2013. — № 7-2. — С. 319-323Travis RC, Key TJ. Oestrogen exposure and breast cancer risk. Breast Cancer Res. 2003;5(5):239. doi: https://doi.org/10.1186/bcr628Amarakoon D, Lee W-J, Tamia G, Lee S-H. Indole-3-Carbinol: Occurrence, Health-Beneficial Properties, and Cellular/Molecular Mechanisms. Annu Rev Food Sci Technol. 2023;14(1):347-366. doi: https://doi.org/10.1146/annurev-food-060721-025531Kit O.I, Franciync E.M., Bandovkina V.A., Shatova Y.S., Komarova E.F., Vereskunova M.I., Kuchkina L.P. Estrone’s metabolites content in the peripheral liquids and tissues among the patients with breast cancer of different ages and reproductive state. Fundamental research. №7, 2013Киселев В.И., Сметник В.П. и др. Индолкарбинол — метод мультитаргетной терапии при циклической мастодинии. // Акушерство и гинекология. — 2013. — №7. — С. 56–62 [Kiselev V.I., Smetnik V.P., Suturina L.V. Indolkarbinol (Indinol Forto) — a method of multitarget therapy with cyclic mastodynia. Obstetrics and gynecology. 2013;7:56–62].Amarakoon D, Lee W-J, Tamia G, Lee S-H. Indole-3-Carbinol: Occurrence, Health-Beneficial Properties, and Cellular/Molecular Mechanisms. Annu Rev Food Sci Technol. 2023;14(1):347-366. doi: https://doi.org/10.1146/annurev-food-060721-025531Ашрафян Л.А., Рожкова Н.И., Прокопенко С.П., с соавт. Влияние препарата индолкарбинола на течение циклической масталгии на фоне доброкачественной дисплазии молочной железы в условиях рутинной клинической практики (исследование «АФРОДИТА»). // Акушерство и гинекология. — 2024. — № 2.doi: https://doi.org/10.18565/aig.2024.35Kiselev V.I., Smetnik V.P., Suturina L.V. Indolkarbinol (Indinol Forto) — a method of multitarget therapy with cyclic mastodynia. Obstetrics and gynecology. 2013;7:56–62.Ashrafyan L, Rozhkova N, Prokopenko S, et al. The influence of indolcarbinol on cyclic mastalgia caused by benign breast dysplasia in routine clinical practice (research "APHRODITA"). Akushrstvo i Ginekologiya. 2024;2;134-142.doi: https://doi.org/10.18565/aig.2024.35Ashrafyan L, Rozhkova N, Prokopenko S, et al. The influence of indolcarbinol on cyclic mastalgia caused by benign breast dysplasia in routine clinical practice (research "APHRODITA"). Akushrstvo i Ginekologiya. 2024;2;134-142.doi: https://doi.org/10.18565/aig.2024.35

The authors declare that there are no conflicts of interest present.